ATE456055T1 - Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden - Google Patents

Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden

Info

Publication number
ATE456055T1
ATE456055T1 AT06765356T AT06765356T ATE456055T1 AT E456055 T1 ATE456055 T1 AT E456055T1 AT 06765356 T AT06765356 T AT 06765356T AT 06765356 T AT06765356 T AT 06765356T AT E456055 T1 ATE456055 T1 AT E456055T1
Authority
AT
Austria
Prior art keywords
brain damage
diagnostic methods
diseases related
polypeptide
subject
Prior art date
Application number
AT06765356T
Other languages
English (en)
Inventor
Denis Francois Hochstrasser
Jean-Charles Sanchez
Original Assignee
Univ Geneve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Geneve filed Critical Univ Geneve
Application granted granted Critical
Publication of ATE456055T1 publication Critical patent/ATE456055T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
AT06765356T 2005-07-14 2006-07-14 Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden ATE456055T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0514435A GB2428240A (en) 2005-07-14 2005-07-14 Diagnostic method for brain damage-related disorders
PCT/GB2006/050207 WO2007007129A2 (en) 2005-07-14 2006-07-14 Diagnostic method for brain damage-related disorders

Publications (1)

Publication Number Publication Date
ATE456055T1 true ATE456055T1 (de) 2010-02-15

Family

ID=34897198

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06765356T ATE456055T1 (de) 2005-07-14 2006-07-14 Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden

Country Status (10)

Country Link
US (1) US9028825B2 (de)
EP (1) EP1902319B1 (de)
JP (2) JP5281397B2 (de)
AT (1) ATE456055T1 (de)
AU (1) AU2006268034B2 (de)
CA (1) CA2613991C (de)
DE (1) DE602006011896D1 (de)
ES (1) ES2336946T3 (de)
GB (1) GB2428240A (de)
WO (1) WO2007007129A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9929140D0 (en) * 1999-12-10 2000-02-02 Univ Geneve Diagnostic assay for stroke
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
PL2021792T3 (pl) 2006-05-09 2013-08-30 Univ British Columbia Rozpuszczone białkowe markery zapalenia stawów
DE102006048201A1 (de) * 2006-10-11 2008-04-17 Ganymed Pharmaceuticals Ag Autoantigene zur verbesserten Diagnose, Prognose und Therapie von entzündlichen neurologischen Erkrankungen
WO2009036336A2 (en) * 2007-09-12 2009-03-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomarkers for motor neuron disease
JP5615181B2 (ja) 2007-11-27 2014-10-29 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 関節炎の予防及び治療のための組成物及び方法
MX340916B (es) 2008-01-18 2016-07-29 President And Fellows Of Harvard College * Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
CA2725548A1 (en) * 2008-05-09 2009-11-12 Duke University Autoantibodies in the detection and treatment of cancer
JP5781436B2 (ja) 2008-08-11 2015-09-24 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカー検出方法およびアッセイ
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US20120071337A1 (en) * 2009-01-26 2012-03-22 Electrophoretics Limited Methods
CA2751090A1 (en) * 2009-01-30 2010-08-05 Electrophoretics Limited Method for the in vitro diagnosis of stroke
WO2010102412A1 (en) 2009-03-11 2010-09-16 Augurex Life Sciences Corporation Compositions and methods for characterizing arthritic conditions
CA2807645C (en) 2009-08-07 2021-09-07 Affinimark Technologies, Inc. Device and methods for the immunological identification of cerebrospinal fluid
AU2010291933B2 (en) * 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
RU2422095C1 (ru) * 2009-12-11 2011-06-27 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ прогнозирования эффективности местной химиотерапии при лечении больных злокачественными опухолями головного мозга
WO2011106322A2 (en) * 2010-02-23 2011-09-01 The Govt. Of The U.S.A. As Represented By The Secretary, Department Of Health And Human Services. Biomarkers for acute ischemic stroke
GB201008541D0 (en) * 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
EP2596132A4 (de) 2010-07-23 2013-12-18 Harvard College Verfahren zur erkennung von anzeichen für krankheiten oder leiden in körperflüssigkeiten
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
TW201209171A (en) 2010-07-23 2012-03-01 Harvard College Methods of detecting diseases or conditions using phagocytic cells
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
WO2012051519A2 (en) * 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
JP6074846B2 (ja) 2010-12-16 2017-02-08 国立研究開発法人産業技術総合研究所 髄液型糖タンパク質の富化及び分離方法、並びにその方法を用いた中枢神経系疾患用マーカーの探索方法及び中枢神経系疾患用マーカー
WO2012152970A1 (es) * 2011-05-06 2012-11-15 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol Método de diagnóstico del ictus isquémico
US20140141458A1 (en) 2011-05-12 2014-05-22 The Johns Hopkins University Assay reagents for a neurogranin diagnostic kit
US9792548B2 (en) 2011-09-22 2017-10-17 Bio-Rad Laboratories, Inc. Systems and methods for biochemical data analysis
PT2768851T (pt) 2011-10-21 2017-09-08 Augurex Life Sciences Corp Antigénios derivados de 14-3-3 citrulinada e utilizações dos mesmos no diagnóstico de artrite reumatoide
US20140370531A1 (en) * 2011-12-14 2014-12-18 University Of Rochester Method of diagnosing mild traumatic brain injury
HK1206425A1 (en) 2012-03-13 2016-01-08 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
WO2013163345A1 (en) * 2012-04-24 2013-10-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury
MX2014015434A (es) 2012-06-15 2015-07-14 Harry Stylli Metodos para detectar enfermedades o condiciones utilizando celulas enfermas en circulacion.
JP2015522260A (ja) 2012-06-15 2015-08-06 ハリー スティリ， 疾患または状態を検出する方法
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
SG11201510701QA (en) * 2013-06-28 2016-01-28 Mcbi Inc Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
US10534003B2 (en) 2013-07-17 2020-01-14 The Johns Hopkins University Multi-protein biomarker assay for brain injury detection and outcome
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
FI20155280A7 (fi) 2015-04-15 2016-10-16 Medicortex Finland Oy Aivovamman prognostisia ja diagnostisia glykaanipohjaisia biomarkkereita
CN105506083B (zh) * 2015-12-24 2018-10-19 孙梅芬 Capg在制备诊断帕金森症产品中的用途
JP6947451B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
WO2018002362A1 (en) * 2016-06-30 2018-01-04 Randox Laboratories Ltd Measurement of fabp for diagnosis
AU2017306558B2 (en) 2016-08-03 2024-09-19 University Of South Florida Reelin compositions for treatment of neurological disorders
CN109791139A (zh) * 2016-08-09 2019-05-21 大塚制药株式会社 使用尿液生物标记的阿兹海默氏症的辅助诊断方法
US10914748B2 (en) 2016-09-08 2021-02-09 UNIVERSITé LAVAL Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing Parkinson's disease
IL265195B2 (en) * 2016-09-16 2025-02-01 Dyax Corp Protein biomarkers for diseases related to the activation system
US11078298B2 (en) 2016-10-28 2021-08-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
KR102466369B1 (ko) * 2020-08-04 2022-11-14 서울대학교병원 자가면역 뇌염의 진단 방법
JP7569552B2 (ja) * 2021-01-29 2024-10-18 国立大学法人東北大学 認知症診断用のバイオマーカー
CN114966045A (zh) * 2022-05-07 2022-08-30 浙江大学 检测抗肌球蛋白轻链1-IgG自身抗体的试剂在制备检测血管内皮损伤的试剂盒中的应用
CN115166260B (zh) * 2022-07-11 2023-06-13 东南大学 血浆脑细胞来源外泌体中维生素d结合蛋白在诊断抑郁症中的应用
CN118624905B (zh) * 2023-07-31 2025-04-01 中国人民解放军总医院第一医学中心 一种糖尿病性肾病诊断的生物标志物和试剂盒及诊断设备
CN120820725B (zh) * 2025-09-17 2026-01-27 上海交通大学医学院附属仁济医院 胶质纤维酸性蛋白和乳酸脱氢酶a亚型在制备诊断颅脑创伤的试剂盒中的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017A (en) * 1845-05-01 Reid r
US3015A (en) * 1843-03-21 Improvement in gilding, silvering
GB225245A (en) * 1923-11-23 1924-12-24 British Thomson Houston Co Ltd Improvements in and relating to elastic fluid turbines
GB322063A (en) * 1928-10-29 1929-11-28 Godwin Stanley Oliver Improvements relating to automatic vehicle-controlled track-signalling devices
JPH09110713A (ja) * 1995-10-13 1997-04-28 Nippon Green Ueebu Kk グルタチオン−ｓ−トランスフェラーゼ活性化剤並びにそれを含む医薬品及び飲食物
EP0914452A2 (de) * 1996-06-17 1999-05-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Ptp-20,pcp-2bdp1, clk und sirp proteine und verwandte produkte
US6541615B1 (en) * 1996-11-15 2003-04-01 Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. SIRP proteins and uses thereof
CA2263063C (en) * 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
WO2001040307A1 (de) * 1999-11-30 2001-06-07 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper gegen signal-regulator-proteine
GB9929140D0 (en) 1999-12-10 2000-02-02 Univ Geneve Diagnostic assay for stroke
WO2001067108A2 (en) 2000-03-10 2001-09-13 Universite De Geneve Diagnostic assay for transmissible spongiform encephalopathies
GB2360089A (en) * 2000-03-10 2001-09-12 Univ Geneve Diagnostic assay for transmisible spongiform encephalopathies
US7608406B2 (en) * 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
AU2003274368B2 (en) 2002-10-30 2008-11-20 Proteome Sciences Plc. Diagnostic method for transmissible spongiform encephalopathies (prion diseases)
DK2341350T3 (en) * 2003-09-20 2018-02-05 Electrophoretics Ltd DIAGNOSTIC PROCEDURE FOR BRAKE INJURY-RELATED DISORDERS BASED ON DJ-1 DETECTION
US20050164238A1 (en) * 2003-09-29 2005-07-28 Biosite, Inc. Methods and compositions for the diagnosis of sepsis
GB0419124D0 (en) 2004-08-27 2004-09-29 Proteome Sciences Plc Methods and compositions relating to Alzheimer's disease
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
CA2590781A1 (en) 2004-12-07 2006-06-15 Electrophoretics Limited Diagnosis of neurodegenerative diseases

Also Published As

Publication number Publication date
WO2007007129A2 (en) 2007-01-18
GB2428240A (en) 2007-01-24
ES2336946T3 (es) 2010-04-19
WO2007007129A3 (en) 2007-05-31
CA2613991C (en) 2017-03-07
EP1902319A2 (de) 2008-03-26
EP1902319B1 (de) 2010-01-20
AU2006268034B2 (en) 2012-02-02
CA2613991A1 (en) 2007-01-18
JP2009501333A (ja) 2009-01-15
US20080220013A1 (en) 2008-09-11
GB0514435D0 (en) 2005-08-17
US9028825B2 (en) 2015-05-12
JP5281397B2 (ja) 2013-09-04
AU2006268034A1 (en) 2007-01-18
JP2013092538A (ja) 2013-05-16
DE602006011896D1 (de) 2010-03-11

Similar Documents

Publication Publication Date Title
ATE456055T1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
Oh et al. Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease
ATE469353T1 (de) Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen
JP2009501333A5 (de)
ATE550658T1 (de) Verfahren für den nachweis oder die diagnose neurodegenerativer erkrankungen oder leiden
UA101167C2 (ru) Фармацевтическая композиция, предназначенная для лечения глазной болезни
WO2010041046A8 (en) Granin proteins as markers of heart disease
WO2007136617A3 (en) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
EP3208617A3 (de) Lipidomische biomarker zur prognose kardiosvaskulärer ergebnisse bei patienten mit erkrankung der herzkranzgefässe ohne statinbehandlung
WO2010084327A3 (en) Methods
WO2006073682A3 (en) Diagnostic test
WO2007080597A3 (en) Polynucleotide and polypeptide sequences and methods for diagnosis
DE602004024539D1 (de) Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben
EA201490883A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛА К α-СИНУКЛЕИНУ ДЛЯ ДИАГНОСТИКИ ПОВЫШЕННОГО УРОВНЯ α-СИНУКЛЕИНА В МОЗГЕ
ATE511651T1 (de) Transglutaminase 6 als diagnostischer indikator für autoimmunerkrankungen
WO2018038352A3 (ko) 치매진단용 자가항체 바이오마커 및 이를 이용한 치매진단 방법
JP2013543581A5 (de)
DK1756571T3 (da) Fremgangsmåde i realtid til detektering af akut inflammatoriske tilstande
ATE483982T1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
BR112013030646A2 (pt) uso diagnóstico de pró-somatostatina
EP2539709A4 (de) Morbus-alzheimer-spezifische änderungen von proteinkinase-c-epsilon- (pkc-epsilon-)proteinspiegeln
ATE454630T1 (de) Verfahren zur diagnose einer erkrankung mit beteiligung eines anti-at1-rezeptor-antikörpers
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
ATE433115T1 (de) Timp-2 als ziel/marker des versagens von beta- zellen
RU2014152876A (ru) Изоформы тропомиозина, связанные с болезнью альцгеймера и умеренными когнитивными нарушениями

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties